[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Puerta de Hierro University Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":245},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,57,86,112,138,162,190,217],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":41,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":56},"100640479","reaction-vad-trial-remote-exercise-training-via-telemedicine-in-patients-with-long-term-ventricular-assist-devices-100640479",false,"NCT07611188","REACTION-VAD Trial: Remote Exercise Training Via Telemedicine in Patients With Long-Term Ventricular Assist Devices","Efficacy and Safety of a Remote Conditioning Program in Patients Supported With a Ventricular Assist Device: THE RE-ACTION-VAD TRIAL.","REACTION-VAD","Inclusion Criteria (must meet all):\n\n* Recent LVAD Implantation (\\\u003C6 months)\n* Clinical stability (defined as meeting all of the following criteria): discharge from the LVAD implantation hospitalization, absence of inotropic medication, hemoglobin \\>9 g\u002FdL, and no active infection.\n* Inability to participate in a supervised rehabilitation program (due to lack of availability, or inability because geographical reasons).\n\nExclusion Criteria (any):\n\n* Functional Inability to Perform Cardiopulmonary Exercise Testing\n* Prior Participation in a Supervised Rehabilitation Program (after the LVAD implantation)","ALL","18 Years",{"count":20,"type":21},78,"ESTIMATED","INTERVENTIONAL",[24],"NA","Current international guidelines recommend that patients with a heart pump (left ventricular assist device, LVAD) participate in supervised exercise cardiac rehabilitation programs. However, not all patients with a heart pump are able to attend to a supervised program on a daily basis.\n\nThe goal of this clinical trial is to determine whether a home-based exercise program helps patients with a heart pump improve their exercise capacity and quality of life, guided by telemedicine tools including a mobile app, smartwatch, and remote medical checkups. The study will also provide information about the safety of this program by monitoring for any issues or symptoms during home activity.\n\nThe trial aims to answer the following questions:\n\n* Does a 12-week remote exercise program improve patients' exercise capacity? This will be measured using the 6-minute walk test and a cardiopulmonary exercise test.\n* Is it safe for patients to follow this exercise plan at home while being monitored through a mobile app and smartwatch?\n* Does the program improve quality of life and reduce feelings of anxiety or depression? This will be assessed using widely validated questionnaires, such as the Kansas City Cardiomyopathy Questionnaire.\n\nResearchers will compare the remote exercise program to standard care, which usually does not include exercise for patients who are unable to attend the hospital daily.\n\nParticipants will:\n\n* Join the study voluntarily after signing a consent form.\n* Be randomly assigned, with a 50% chance of being in either the exercise group (following a structured plan with a mobile app) or the usual care group (receiving general written advice), to see which approach works best for recovery.\n* Follow a 12-week home-based routine if in the exercise group, including warm-up routine, walking or cycling, respiratory exercises, and light strength training, all supported by the mobile app, smartwatch, and professional monitoring.\n* Visit the hospital three times over six months for medical checkups, including walking and exercise tests, blood analyses, and questionnaires about physical and emotional health.",[27,28,29,30,31,32,33,34,35,36,37,38,39,40],"Heart Failure","Advanced Heart Failure","Left Ventricular Assist Device","LVAD","Cardiac Rehabilitation","Telemedicine","Remote Exercise","Ventricular Assist Device","Exercise Training","Conditioning Therapy","Cardiopulmonary Exercise Test","Six Minute Walk Test","Quality of Life","Telerehabilitation",[29,28,27,31,42,32,43,39,37,40],"Remote rehabilitation","6 minute walking test","NOT_YET_RECRUITING","2026-05-20",{"date":47,"type":48},"2026-05-28","ACTUAL",{"date":50,"type":21},"2026-05",{"date":52,"type":21},"2030-12",{"name":54,"class":55},"Puerta de Hierro University Hospital","OTHER",10,{"id":58,"slug":59,"hasResults":11,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":4,"eligibilityCriteria":63,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":64,"targetDuration":4,"studyType":22,"phases":66,"briefSummary":67,"conditions":68,"keywords":71,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},"100454486","efficacy-of-hofa-versus-hydrocolloid-dressings-in-the-prevention-of-pus-in-critically-ill-prone-patients-100454486","NCT05198167","Efficacy of HOFA Versus Hydrocolloid Dressings in the Prevention of PUs in Critically Ill Prone Patients","Efficacy of Hyperoxygenated Fatty Acids Versus Hydrocolloid Dressings in the Prevention of Pressure Ulcers in Critically Ill Prone Patients","Inclusion Criteria:\n\nAll patients in prone position admitted to participating ICU who agree to be included in the study or, if they are unable to communicate, the consent is authorized by their referring family member.\n\nExclusion Criteria:\n\nPatients with previous pressure ulcers in the following prone-related locations: shoulders, thorax, genitals, iliac crest, knees, ankles, facial.",{"count":65,"type":21},262,[24],"Introduction: Prone position (PP) treatment as a rescue strategy for patients with acute respiratory distress syndrome (ARDS) is a technique increasingly used in our daily practice and, as a result of the current health situation due to SARS COV-2, has become the treatment of choice for many patients. Many of the associated complications can be considerably reduced with the implementation of standardized procedures and a team trained and specialized in this technique and its subsequent care.\n\nAim: To evaluate the efficacy of the use of Hyperoxygenated Fatty Acids (HOFA) compared to the use of hydrocolloid dressings (HCD) in the prevention of Pressure ulcers (PUs) occurrence in critically ill patients in prone position.\n\nMethods: A randomized clinical trial will be conducted to compare the occurrence of PUs and other complications in patients undergoing PP in the ICU of the HUPHM. Two care groups will be formed in which HOFA and hydrocolloid dressings will be used, respectively, following a strict care protocol previously established in the unit. In addition, other variables related to medical and nursing treatment that may influence the appearance of PUs and other complications associated with PP will also be analyzed.\n\nScientific relevance: PUs have a major socioeconomic and quality of life impact on patients. Dressings and topical agents for prevention are widely used, however, it is unclear which treatment is most effective in preventing PUs in the prone patient.\n\nKeywords: Prone Position; Nursing care; Pressure ulcer; Fatty acids; Prevention; Complications.",[69,70],"Prone Position","Pressure Ulcer",[72,73,74,75],"Nursing Care","Fatty acids","Prevention","Complications","RECRUITING","2026-05-12",{"date":79,"type":48},"2026-05-15",{"date":81,"type":48},"2021-06-12",{"date":83,"type":21},"2027-07",{"name":54,"class":55},1,{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":94,"targetDuration":4,"studyType":22,"phases":96,"briefSummary":98,"conditions":99,"keywords":102,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":4},"100632104","phase-2-fecal-microbiota-transplant-vs-standard-treatment-for-recurrent-non-obstructive-cholangitis-100632104","NCT07509346","Fecal Microbiota Transplant vs Standard Treatment for Recurrent Non-Obstructive Cholangitis","Multicenter Clinical Trial to Evaluate the Efficacy and Safety of Fecal Microbiota Transplantation Versus Standard Treatment in Patients With Recurrent Non-Obstructive Acute Cholangitis - COLANBIOTA Trial","COLANBIOTA","Inclusion criteria - Patients ≥18 years of age who have had ≥2 episodes of acute cholangitis in the past year.\n\nExclusion criteria\n\n* Oral intolerance or inability to swallow capsules.\n* Pregnancy or breastfeeding.\n* Any clinically significant disease (other than RAC) such as disseminated malignancy or organ failure resulting in relevant cardiac, hepatic, pulmonary, or neurodegenerative disease with an expected survival of less than one year.\n\nInability to understand the study, sign the informed consent, and\u002For collect stool samples.\n\n\\- RAC due to the presence of choledocholithiasis (any number of stones in the biliary tract) or extrahepatic bile duct stricture that cannot be resolved by surgical or endoscopic treatment. Lack of resolution of extrahepatic biliary obstruction is defined as failure to remove all stones, or a residual diameter in stricture cases of less than 75% of the bile duct diameter above and below the stricture, even after balloon dilation and\u002For biliary stent placement",{"count":95,"type":21},44,[97],"PHASE2","Patients with abnormalities of the biliary tract (the system that connects the liver to the small intestine and allows bile to flow) are prone to the development of strictures, dilations, or other problems that impede bile flow and promote the formation of gallstones. All of this leads to the development of infections in this anatomical region known as cholangitis. These infections typically require the patient to be admitted to the hospital, either to a general ward or even the ICU. These are, therefore, serious infections that threaten the patient's survival. Unfortunately, one-quarter of these patients experience not just one, but multiple infections of this type over an extended period of time. This condition is called acute recurrent cholangitis (ARC).\n\nIt is important to note that the antibiotics used to treat these repeated infections lead to the selection of more resistant and virulent bacteria that remain in the intestine for months or years and, in turn, promote the recurrence of these infectious episodes. ARC affects a more vulnerable population, which, combined with the proliferation of resistant bacteria, increases the risk of serious complications and a reduced response to available treatments.\n\nReplacing these dangerous gut bacteria with bacteria from healthy donors is a strategy that has proven effective in reducing recurrent urinary tract infections. A similar approach has been successful in patients with chronic vaginal infection (vaginosis). This gut microbiota replacement is currently being investigated for a wide range of diseases affecting various sites, with promising results in some cases. There is strong evidence that this strategy may also be effective in patients with recurrent episodes of cholangitis.\n\nThe procedure is considered very safe and is subject to strict safety measures to prevent risks to the recipient of these bacteria (requirements similar to those used for blood transfusions). If this strategy proves effective, it could reduce patient suffering and even mortality, as well as save money spent on hospital stays and medications, and contribute to reducing antibiotic use and the emergence of bacterial resistance. Even if no significant clinical benefit is demonstrated in this clinical setting, the information obtained will contribute to increasing knowledge about the role of the fecal microbiota, the technical and scientific aspects of fecal microbiota transplantation, and its potential uses. It should be noted that a patient association called ALBI España (Association for the Fight Against Inflammatory Biliary Diseases) has participated in the study's design and strongly supports this research, which could lead to a reduction in mortality among its patients and a reduction in adverse effects and costs associated with hospital admissions and antibiotic use.\n\nIn summary, the use of FMT in patients with AC could have a significant impact on treatment effectiveness, reducing new episodes of cholangitis. This would improve patients' quality of life-including their physical, emotional, and social well-being-by reducing hospitalizations and associated complications. Another clear benefit would be the reduction in the proliferation of resistant bacteria and a lower use of antibiotics. The use of TMF would increase the autonomy of the National Health System (SNS) by enabling it to develop and manage non-commercial, non-profit therapies with low production costs, which would guarantee equitable access for patients to an effective and safe therapy.",[100,101],"Cholangitis Acute","Recurrence",[103],"FMT for recurrent acute cholangitis","2026-04-07",{"date":106,"type":48},"2026-04-13",{"date":108,"type":21},"2026-06-01",{"date":110,"type":21},"2029-12-31",{"name":54,"class":55},{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":118,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":17,"minAge":120,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":22,"phases":123,"briefSummary":124,"conditions":125,"keywords":126,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":85},"100619924","impact-of-cardiac-rehabilitation-adapted-for-patients-with-heart-failure-100619924","NCT07350941","Impact of Cardiac Rehabilitation Adapted for Patients With Heart Failure","RAP-IC Study: Impact of Cardiac Rehabilitation Adapted for Patients With Heart Failure","RAP-IC","Inclusion Criteria:\n\n* Patients hospitalized for acute heart failure in a stable phase (on a stable dose or tapering intravenous diuretics for at least 48 hours, without intravenous inotropes or vasodilators for \\>72 hours).\n* Baseline functional class II-III\n* Age ≥ 65 years\n* Able to walk \\>4 meters\n* Any range of left ventricular ejection fraction\n\nExclusion Criteria:\n\n* Moderate to severe dementia\n* Cardiac or other disease with a life expectancy \\\u003C12 months\n* Institutionalized patients or unable to travel to the rehabilitation center\n* Functional class I or IV\n* Uncontrolled arrhythmias\n* Inability to perform a basic exercise protocol","65 Years",{"count":122,"type":21},114,[24],"The aim of the study is to evaluate whether a tailored cardiac rehabilitation program, initiated during hospitalization and continued after discharge, can improve functional capacity, mobility, and quality of life in patients over 65 years old with heart failure.",[27],[27,127,128,129],"Cardiac rehabilitation","Cardiopulmonary stress test","Functional capacity","2026-01-10",{"date":132,"type":48},"2026-01-20",{"date":134,"type":21},"2026-01-30",{"date":136,"type":21},"2028-01",{"name":54,"class":55},{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":144,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":146,"targetDuration":4,"studyType":148,"phases":4,"briefSummary":149,"conditions":150,"keywords":152,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":85},"100538048","effect-of-acetazolamide-on-diuresis-and-natriuresis-in-patients-with-acute-heart-failure-sandi-study-100538048","NCT06285760","Effect of Acetazolamide on Diuresis and Natriuresis in Patients With Acute Heart Failure (SANDI STUDY)","SANDI STUDY: Effect of Acetazolamide on Diuresis and Natriuresis in Patients With Acute Heart Failure.","SANDI","Inclusion Criteria:\n\n* Patients admitted for acute heart failure and ≥ 1 clinical sign of volume overload (edema, ascites, or pleural effusion).\n* NTproBNP levels \\>1000 pg\u002FmL or BNP \\>250 ng\u002FmL on admission.\n* Under treatment with furosemide and iSGLT2 according to European guidelines and indication of association of another diuretic due to residual congestion data defined by ADVOR SCORE\\>1.\n\nExclusion Criteria:\n\n* Systolic blood pressure \\\u003C90 mmHg or mean arterial pressure \\\u003C 65 mmHg.\n* Maintenance treatment with acetazolamide\u002F Treatment with acetazolamide in the month prior to inclusion in the study.\n* Anticipated need for intravenous inotropes, vasopressors or nitroprusside during the study.\n* Contraindication to ISGLT2.\n* Type 1 diabetes mellitus\n* GFR \\\u003C 20 ml\u002Fmin\u002Fm2 or renal replacement therapy\u002Fultrafiltration at any time prior to the study.\n* Anticipated exposure to nephrotoxic agents, such as iodinated contrast during admission.\n* Concurrent diagnosis of acute coronary syndrome.\n* History of congenital heart disease requiring surgical correction.\n* History of cardiac transplantation and\u002For ventricular assist device.\n* Pregnant or breastfeeding patients.\n* Inability to adequately collect diuresis.\n* Serum potassium less than 3.5 mEq\u002FL.\n* Venous pH \\\u003C7.30\n* Severe aortic stenosis or obstructive hypertrophic cardiomyopathy.\n* Sulfonamide allergy, liver cirrhosis, renal lithiasis.",{"count":147,"type":21},64,"OBSERVATIONAL","The goal of this observational study is to assess the natriuretic effect of intravenous acetazolamide in patients admitted with heart failure and persistent congestion despite treatment with intravenous furosemide and sodium-glucose cotransporter type 2 (iSGLT2) inhibitors.\n\nThe main question it aims to answer is whether there is a difference in natriuresis 24 hours after acetazolamide association to medical treatment recommended by the guidelines (furosemide and ISGLT2).",[27,151],"Persistent Congestion",[153],"Acetazolamide","2025-12-19",{"date":156,"type":48},"2025-12-29",{"date":158,"type":48},"2024-03-01",{"date":160,"type":21},"2026-12-31",{"name":54,"class":55},{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":168,"eligibilityCriteria":169,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":170,"targetDuration":4,"studyType":22,"phases":172,"briefSummary":173,"conditions":174,"keywords":176,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":85},"100614565","trimodal-prehabilitation-in-gastrointestinal-cancer-100614565","NCT07281248","TRIMODAL PREHABILITATION IN GASTROINTESTINAL CANCER","TRIMODAL PREHABILITATION PROGRAM IN PATIENTS WITH GASTROINTESTINAL CANCER DURING NEOADJUVANT TREATMENT: A PILOT STUDY","PREDIGEST","Inclusion Criteria:\n\n* More than 18 years old\n* ECOG 0-2\n* Being able to complete the mile-time test\n* Stages I-III\n* Being able to understand the informed consent\n* Gastrointestinal cancer diagnosed\n\nExclusion Criteria:\n\n* Metastatic cancer",{"count":171,"type":21},30,[24],"Digestive cancers account for a substantial proportion of oncological patients, representing over 20% of cases treated in hospitals, and are generally managed through a multidisciplinary approach that has markedly improved survival outcomes over recent decades. Surgical resection remains the cornerstone of curative treatment, often preceded by neoadjuvant chemotherapy, radiotherapy, or combined modalities. Notably, a significant proportion of patients eligible for abdominal surgery are older adults, with approximately one in three being over 75 years of age. Advances such as Enhanced Recovery After Surgery (ERAS) protocols and the centralization of complex surgical procedures have contributed to better outcomes, including higher rates of radical resections, improved survival, reduced postoperative complications, and shorter hospital stays.\n\nWhile some risk factors are non-modifiable, such as age, sex, tumor stage, comorbidities, and tumor biology, several modifiable factors can be optimized prior to surgery to improve postoperative outcomes. These include smoking cessation, enhancement of aerobic capacity and muscular strength, nutritional optimization, emotional resilience, and correction of anemia or other metabolic derangements. Preoperative exercise, ideally embedded within a multimodal prehabilitation program, is recommended for all patients undergoing major surgery. The neoadjuvant period represents a valuable window to implement trimodal prehabilitation strategies encompassing physical exercise, nutritional support, and psychological interventions, aimed at reducing postoperative complications, shortening hospital length of stay, and improving functional recovery.\n\nPhysical fitness in this context is multidimensional, encompassing aerobic capacity, muscle strength, and body composition. Aerobic capacity predicts postoperative complications and length of hospital stay, while low muscle strength and sarcopenia are associated with higher morbidity and poorer prognosis. Inspiratory muscle training can further reduce pulmonary complications and accelerate recovery. Nutritional status is a critical determinant of surgical outcomes in gastrointestinal cancer, with malnutrition affecting up to 80% of patients at diagnosis. Comprehensive assessment, including dietary intake, anthropometric measurements, physical examination, and biomarkers such as albumin and transferrin, is essential, and targeted interventions including protein supplementation, pancreatic enzyme replacement, or tailored dietary strategies should be implemented when indicated. Body composition, particularly sarcopenia and cachexia, is closely linked to both nutrition and exercise, and can be assessed through imaging techniques such as DXA, CT, or MRI, or via bioelectrical impedance in research settings, with simpler bedside assessments used in clinical practice.\n\nEmotional wellbeing also plays a significant role, as preoperative anxiety and depression can negatively influence recovery, adherence to rehabilitation, and overall quality of life. Psychological support, stress management, and behavioral interventions can improve patient engagement and enhance outcomes. The physiological principles of hormesis and cross-stressor adaptation suggest that controlled exercise can improve resilience to both physical and psychological stressors, including the stress of surgery itself. Additional modifiable factors such as absolute cessation of alcohol and tobacco, glycemic control in diabetic patients, correction of anemia (including iron deficiency), and frailty assessment in older adults are critical components of preoperative optimization.\n\nMajor abdominal surgery carries substantial risk, including infections, bleeding, and anastomotic complications, which directly impact quality of life and lengthen hospitalization. Evidence from randomized controlled trials indicates that multimodal prehabilitation effectively reduces postoperative complications and shortens hospital stay. However, motivating patients to engage in exercise during neoadjuvant therapy can be challenging due to treatment-related fatigue, nausea, and other side effects. Integrating behavioral theories such as Self-Determination Theory and the Theory of Planned Behavior can enhance intrinsic motivation by fostering autonomy, competence, and relatedness, and addressing attitudes, subjective norms, and perceived behavioral control, ultimately promoting adherence to prehabilitation programs and optimizing postoperative recovery.",[175],"Digestive Neoplasms",[177,178,179,180,181],"cancer","prehabilitation","gastrointestinal","exercise","trimodal","2025-12-10",{"date":184,"type":48},"2025-12-15",{"date":186,"type":48},"2025-08-28",{"date":188,"type":21},"2027-09-01",{"name":54,"class":55},{"id":191,"slug":192,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":196,"eligibilityCriteria":197,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":198,"targetDuration":4,"studyType":22,"phases":199,"briefSummary":201,"conditions":202,"keywords":204,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":85},"100570806","phase-3-effect-of-angiotensin-receptorneprilysin-inhibitors-on-transthyretin-cardiac-amyloidosis-and-heart-failure-with-reduced-ejection-fraction-100570806","NCT06712030","Effect of Angiotensin Receptor\u002FNeprilysin Inhibitors on Transthyretin Cardiac Amyloidosis and Heart Failure with Reduced Ejection Fraction","Effect of Pharmacological Treatment with Angiotensin Receptor\u002FNeprilysin Inhibitors on Transthyretin Cardiac Amyloidosis and Heart Failure with Reduced Ejection Fraction (SAVA-TTR)","SAVA-TTR","Inclusion Criteria:\n\n* Patients ≥ 18 years of age of both sexes.\n* Patients diagnosed with ATTR cardiac amyloidosis as indicated in guidelines, both in its hereditary form (ATTRv) or wild-type form (ATTRwt).\n* Patients initially evaluated or under follow-up in Cardiomyopathy\u002FHeart Failure\u002FAmyloidosis Units at participating centers.\n* Heart failure and reduced ejection fraction: LVEF ≤40%, in functional class I, II, or III according to the New York Heart Association (NYHA).\n\nExclusion Criteria:\n\n* NYHA Functional Class IV.\n* Stage 4 and 5 chronic kidney disease (creatinine clearance by CKD-EPI \\\u003C30 mL\u002Fmin\u002F1.73m²).\n* Hyperkalemia (blood potassium levels \\> 5.4 mmol\u002FL).\n* Hypotension defined as systolic blood pressure (SBP) \\\u003C100 mmHg on two consecutive measurements.\n* Treatment with ACE inhibitors, ARBs, or sacubitril\u002Fvalsartan at the time of enrollment.\n* History of angioedema or hypersensitivity to ACE inhibitors or ARBs.\n* Treatment with TTR gene silencers or diflunisal.\n* Participation in another clinical trial.\n* Pregnancy, breastfeeding, or fertile women unwilling to use adequate contraception throughout the study duration.\n* Any condition that, in the investigator's opinion, compromises participation in the study.",{"count":122,"type":21},[200],"PHASE3","Prospective, randomized, multicenter, open-label clinical trial to evaluate the safety and efficacy of Sacubitril\u002FValsartan (Sac\u002FVals) compared to no initiation of the drug in patients with transthyretin cardiac amyloidosis (ATTR) and heart failure with reduced ejection fraction (LVEF ≤40%). The primary objective is to determine the impact of Sac\u002FVals treatment on systolic function by assessing the change in LVEF on echocardiogram at 12-month follow-up.",[203],"Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)",[205,206,207,208],"Heart failure","Reduced ejection fraction","Angiotensin receptor\u002Fneprilysin inhibitors","Sacubitril valsartan","2024-11-26",{"date":211,"type":48},"2024-12-02",{"date":213,"type":21},"2025-01",{"date":215,"type":21},"2027-06",{"name":54,"class":55},{"id":218,"slug":219,"hasResults":11,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":223,"eligibilityCriteria":224,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":225,"targetDuration":4,"studyType":148,"phases":4,"briefSummary":227,"conditions":228,"keywords":230,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":243,"locationsCount":244},"100492165","usefulness-of-pet-ct-for-invasive-fungal-infection-100492165","NCT05688592","Usefulness of PET-CT for Invasive Fungal Infection","A Prospective Multicenter Study to Determine the Usefulness of Systematic 18-FDG-PET-TC for the Management of Invasive Fungal Infection (PETIFI Project)","PETIFI","Inclusion criteria:\n\n* 18-year-old adult patients\n* who are admitted with a diagnosis of invasive fungal infection\n* who able to undergo a one 18F-FDG PET-CT\n* who give their informed consent.\n\nExclusion criteria:\n\n* concomitant active bacterial infection likely to produce uptake in organs and tissues\n* recent surgery in the area of the IFI (in the previous 3 months)\n* other medical conditions that interfere with the development of the study ( e.g., inability to tolerate the performance of the test during the required time, pregnancy)\n* terminal situation.",{"count":226,"type":21},224,"The goal of this national multicenter prospective cohort study is to learn about the added value of 18F-FDG (18F-2-fluoro-2-deoxy-D-glucose) PET-CT in invasive fungal disease management. The main questions it aims to answer are:\n\n1. Does the use of 18F-FDG PET-CT allow a better characterization of invasive fungal infection (IFI) (performance) compared to the exclusive use of conventional radiological studies in terms of extension\u002Fstaging and monitoring of response\u002Ffollow-up ?\n2. Does the systematic and protocolized use of 18F-FDG PET-CT in IFI allow a better management of patients with IFI and increase the prognostic value of the initial evaluation? Participants will undergo systematically a 18F-FDG PET-CT as part of the work-up of their invasive fungal disease. Researchers will compare the performance of 18F-FDG PET-CT with standard management without 18F-FDG PET-CT to see if adds value (diagnostic, prognostic, and changes in management).",[229],"Invasive Fungal Infections",[231,232,233,234,235],"invasive fungal infection","PET-CT","management","staging","monitoring response","2024-11-04",{"date":238,"type":48},"2024-11-06",{"date":240,"type":48},"2023-04-27",{"date":242,"type":21},"2024-12-01",{"name":54,"class":55},14,""]